The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > REGULATORY
REGULATORY
- Access System for Unapproved Drugs to Be Submitted at Next Ordinary Diet Session “at the Latest”: Mr Kawai of DPJ
June 21, 2012
- MHLW Calls for OTC Switch for Hyaluronate Sodium
June 21, 2012
- Establishment of Third-Party Organization “Historical”: DPJ Member Kawai
June 20, 2012
- PMDA’s Science Committee Holds 1st Meeting; Will Work to Improve Review Quality through Exchanges with Researchers
June 20, 2012
- MHLW Committee Compiles Discussion Points on System for Public Release of Drug Damage Documents
June 20, 2012
- MHLW Withdraws Orphan Drug Designation for Somatropin
June 18, 2012
- MHLW Designates 5 Products, Including CLL Treatment, as Orphan Drugs
June 18, 2012
- DPJ Approves Draft Bill to Establish 3rd-Party Organization; Will Seek Discussions with Opposition
June 18, 2012
- Developed or Developing Countries: Which Side Is Right on Humanitarian Aid?
June 18, 2012
- MHLW Selects Kitasato Univ. Hospital, FBRI as Base for Japan-Led Global Clinical Research
June 15, 2012
- Mr Umemura of DPJ Proposes Obligatory Use of Generics for Welfare Recipients
June 15, 2012
- MHLW Study Group Might Postpone Concrete Conclusion on Relief System for Victims of Health Damage Due to Anticancer Drugs
June 13, 2012
- Ryukaikon’s Working Team Prepares to Start Operations by End of June; Beginning with Exchange of Opinions between JPWA, NPhA
June 13, 2012
- With Consumption Tax Hike in 2015, “Focus on Whether to Conduct Market Price Survey”: EAD Director Kamata
June 12, 2012
- PAFSC Committee Gives Green Light to OTC Switching of Hyaluronate Sodium
June 11, 2012
- Committee on Non-Prescription Drugs Recommends Approval for Switch OTC Versions of Allegra
June 11, 2012
- Medical Community Expresses Caution on Deferment of Experimental Animal Regulations by DPJ
June 8, 2012
- Gov’t Council Finalizes 5-Year Medical Innovation Strategy Calling for Creation of Drug Discovery Support Network
June 8, 2012
- Expert Subcommittee Begins Discussions on Pricing of Long-Listed Drugs with Focus on Differences from Generic Prices
June 8, 2012
- Drug Cost Ratio in FY2009 was 22.3%, Up 1.1 Points from Previous Year: MHLW
June 8, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…